nCounter®
Tumor Signaling 360™ Panel

Helping Your Research

As therapeutics that target tumor signaling evolve, a greater understanding of tumor signaling is required as well as a better understanding of the interactions of tumor cells with the tissue milieu. The Tumor Signaling 360 Panel is intended to play this exact role, enabling deeper profiling of the tumor that is complete, yet focused on signaling pathways of interest for targeted therapeutic development. Covering hundreds of genes involved in tumorigenesis, metastasis, and inflammation, the nCounter Tumor Signaling 360 Panel offers a holistic view of the biology of the tumor, microenvironment, and immune response with an emphasis on dysfunctional cell signaling in cancer.

  • Profile 40+ pathways involved in tumor biology, immune evasion, and remodeling of the microenvironment.
  • Identify targets for novel therapeutics
  • Understand the mechanism of action of targeted therapies
  • Determine the extent of anti-tumor immune response with the Tumor Inflammation Signature
  • Quantify the presence and relative abundance of 14 different immune cell types

Inspired by systems biology approaches to cancer research, NanoString’s 360 Series Panel Collection gives you a 360° view of gene expression by combining carefully-curated content involved in the biology of the tumor, microenvironment, and the immune response into a single holistic assay. Each panel contains the 18-gene Tumor Inflammation Signature (TIS) that measures a peripherally-suppressed, adaptive immune response and has been shown to correlate with response to checkpoint inhibitors.

tumor promotion inflammation illustration

How it Works

The nCounter 360 series of cancer gene expression panels have been developed to comprehensively profile the tumor, immune response, and microenvironment. Genes included in the Tumor Signaling 360 Panel are organized and linked to various advanced analysis modules to allow for efficient analysis of cell signaling pathways.

Advanced Analysis Modules available for Tumor Signaling 360:

  • Normalization
  • Quality Control
  • Individual Pathway Analysis
  • Cell Profiling
  • Differential Expression
  • Gene Set Analysis
  • Built-in compatibility for Panel-Plus and Protein Analysis

 

Panel Selection Tool

Find the gene expression panel for your research with Panel Pro

Find Your Panel

Product Information

Core Themes and Annotations
Tumor Inflammation Signature
Immune Cell Type Gene Coverage
Product Specifications
Catalog Information
Product Comparison
Core Themes and Annotations
Tumor Inflammation Signature

The Tumor Inflammation Signature includes 18 functional genes known to be associated with response to PD-1/PD-L1 inhibitors.

Includes four areas of Immune Biology: IFN-ү-responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance genes.

The tumor inflammation gene expression signature highlights the complex biology of the host immune microenvironment.

View publication and video.

  1. Ayers, Mark, et al. “IFN-y-related mRNA profile predicts clinical response to PD-1 blockade.” The Journal of Clinical Investigation 127.8 (2017).
Immune Cell Type Gene Coverage

Platform Specifications (*Does not apply to Prosigna® Breast Cancer Prognostic Gene Signature Assay (1))

Product Specifications
Catalog Information
Product Comparison

360 Series Product Comparison

Fully-annotated gene lists in Excel format are available for each of the 360 Panels. The table below compares the biology coverage of the 360 Panels across the tumor, microenvironment, and the immune response to that of the PanCancer Panels Collection.

Related Resources

See All Resources
Product Bulletin Tumor Signaling 360 Panel – Product Bulletin
Blog Post How the Field of Immuno-Oncology is Changing Fast
Blog Post From an Egyptian Papyrus to the Hallmarks of Cancer: A Journey through the Development of Knowledge in Oncology Research
Blog Post Five Key Milestones in the History of Research in Cancer Biology
Manual/Instructions NanoU Training Videos

Publications

View All Publications

Presence of onco-fetal neighborhoods in hepatocellular carcinoma is associated with relapse and response to immunotherapy

Onco-fetal reprogramming of the tumor ecosystem induces fetal developmental signatures in the tumor microenvironment, leading to immunosuppressive features. Here, we employed single-cell RNA sequencing, spatial transcriptomics and bulk RNA sequencing to delineate specific cell subsets involved in hepatocellular carcinoma (HCC) relapse and response to immunotherapy.

Molecular analysis of XPO1 inhibitor and gemcitabine–nab‐paclitaxel combination in KPC pancreatic cancer mouse model

Background: The majority of pancreatic ductal adenocarcinoma (PDAC) patients experience disease progression while on treatment with gemcitabine and nanoparticle albumin‐bound (nab)‐paclitaxel (GemPac) necessitating the need for a more effective treatment strategy for this refractory disease. Previously, we have demonstrated that nuclear exporter protein exportin 1 (XPO1) is a valid therapeutic target in PDAC, and the selective inhibitor of nuclear export selinexor (Sel) synergistically enhances the efficacy of GemPac in pancreatic cancer cells, spheroids and patient‐derived tumours, and had promising activity in a phase I study.

Spatial transcriptomic interrogation of the tumour-stroma boundary in a 3D engineered model of ameloblastoma

Stromal cells are key components of the tumour microenvironment (TME) and their incorporation into 3D engineered tumour-stroma models is essential for tumour mimicry. By engineering tumouroids with distinct tumour and stromal compartments, it has been possible to identify how gene expression of tumour cells is altered and influenced by the presence of different stromal cells.

Request a Quote

Contact our helpful experts and we’ll be in touch soon.